Antithyroid Drugs

Document Type : Review Paper

Authors

Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Abstract

The thionamide drugs, i.e. carbimazole and its metabolite methimazole (MMI), and
propylthiouracil (PTU) have extensively been used in the management of various forms of
hyperthyroidism over the past eight decades. This review aims to summarize different aspects
of these outstanding medications. Thionamides have shown their own acceptable efficacy and
even safety profiles in treatment of hyperthyroidism, especially GD in both children and adults
and also during pregnancy and lactation. Of the antithyroid drugs (ATDs) available, MMI is
the preferred choice in most situations taking into account its better efficacy and less adverse
effects accompanied by once-daily dose prescription because of a long half-life and similar cost.
Considering the more severe teratogenic effects of MMI, PTU would be the selected ATD for
treatment of hyperthyroidism during pre-pregnancy months and the first 16 weeks of gestation.
Recent studies have confirmed the efficacy and safety of long-term MMI therapy with low
maintenance doses for GD and toxic multinodular goiter. Despite the long-term history of ATD
use, there is still ongoing debate regarding their pharmacology and diverse mechanisms of action,
viz. their immunomodulatory effects, and mechanisms and susceptibility factors to their adverse
reactions.

Keywords

Main Subjects


(1) Ross DS, Burch HB, Cooper DS, Greenlee MC,
Laurberg P, Maia AL, Rivkees SA, Samuels
M, Sosa JA and Stan MN. 2016 American
thyroid association guidelines for diagnosis and
management of hyperthyroidism and other causes
of thyrotoxicosis. Thyroid (2016) 26: 1343-421.
(2) Kennedy T. Thio-ureas as goitrogenic substances.
Nature (1942) 150: 233-4.
(3) Astwood EB, Sullivan J, Bissell A and Tyslowitz
R. Action of certain sulfonamides and of thiourea
upon the function of the thyroid gland of the rat.
Endocrinology (1943) 32: 210-25.
(4) Astwood E. Treatment of hyperthyroidism with
thiourea and thiouracil. JAMA (1943) 122: 78-81.
(5) Astwood E. Thiouracil treatment in
hyperthyroidism. J. Clin. Endocrinol. (1944) 4:
229-48.
(6) Tominaga T, Yokoyama N, Nagataki S, Cho
BY, Koh CS, Chen JL and Shi Y. International
differences in approaches to 131I therapy for
Graves’ disease: case selection and restrictions
recommended to patients in Japan, Korea, and
China. Thyroid (1997) 7: 217-20.
(7) Bartalena L, Burch H, Burman K and Kahaly G. A
2013 European survey of clinical practice patterns
in the management of Graves’ disease. Clin.
Endocrinol. (2016) 84: 115-20.
(8) Beshyah SA, Khalil AB, Sherif IH, Benbarka MM,
Raza SA, Hussein W, Alzahrani AS and Chadli A. A
survey of clinical practice patterns in management
of Graves disease in the Middle East and North
Africa. Endocr. Pract. (2016) 23: 299-308.
(9) Burch HB, Burman KD and Cooper DS. A
2011 survey of clinical practice patterns in
the management of Graves’ disease. J. Clin.
Endocrinol. Metab. (2012) 97: 4549-58.
9
Antithyroid drugs
(10) Davidson B, Soodak M, Neary JT, Strout
HV, Kieffer JD, Mover H and Maloof F. The
irreversible inactivation of thyroid peroxidase
by methylmercaptoimidazole, thiouracil, and
propylthiouracil in-vitro and its relationship to invivo findings. Endocrinology (1978) 103: 871-82.
(11) Cooper DS. Treatment of Thyrotoxicosis. In:
Braverman LE and Cooper DS. (eds.) Werner and
Ingbar's the Thyroid: A Fundamental and Clinical
Text. 10th ed. Lippincott Williams and Wilkins,
USA (2012) 492-516.
(12) Papapetrou PD, Mothon S and Alexander WD.
Binding of the 35S of 35S-propylthiouracil by
follicular thyroglobulin in-vivo and in-vitro. Eur. J.
Endocrinol. (1975) 79: 248-58.
(13) Monaco F, Santolamazza C, De Ros I and
Andreoli A. Effects of propylthiouracil and
methylmercaptoimidazole on thyroglobulin
synthesis. Eur. J. Endocrinol. (1980) 93: 32-6.
(14) Kuiper GG, Kester MH, Peeters RP and Visser
TJ. Biochemical mechanisms of thyroid hormone
deiodination. Thyroid (2005) 15: 787-98.
(15) Burch HB and Cooper DS. Anniversary review:
antithyroid drug therapy: 70 years later. Eur. J.
Endocrinol. (2018) 179: R261-R74.
(16) Madec A, Allannic H, Genetet N, Gueguen M,
Genetet G, Fauchet R, Stefanutti A and Orgiazzi
J. T lymphocyte subsets at various stages of
hyperthyroid Graves’ disease: effect of carbimazole
treatment and relationship with thyroid-stimulating
antibody levels or HLA status. J. Clin. Endocrinol.
Metab. (1986) 62: 117-21.
(17) Eisenstein Z, Engelsman E, Weiss M, Kalechman
Y and Sredni B. Production of and response to
interleukin-2 in Graves’ disease. J. Clin. Immunol.
(1988) 8: 349-55.
(18) Bagnasco M, Venuti D, Ciprandi G, Pesce
G, Paolieri F and Canonica G. The effect of
methimazole on the immune system is unlikely to
operate directly on T lymphocytes. J. Endocrinol.
Invest. (1990) 13: 493-9.
(19) Corrales J, Orfao A, López A and Mories M. Serial
analysis of the effects of methimazole therapy on
circulating B cell subsets in Graves’ disease. J.
Endocrinol. (1996) 151: 231-40.
(20) Zantut-Wittmann DE, Tambascia MA, da Silva
Trevisan MA, Pinto GA and Vassallo J. Antithyroid
drugs inhibit in-vivo HLA-DR expression in
thyroid follicular cells in Graves’ disease. Thyroid
(2001) 11: 575-80.
(21) Weetman A, Holt ME, Campbell A, Hall R and
McGregor A. Methimazole and generation of
oxygen radicals by monocytes: potential role in
immunosuppression. Br. Med. J. (Clin. Res. Ed.)
(1984) 288: 518-20.
(22) Kim H, Lee TH, Hwang YS, Bang MA, Kim
KH, Suh JM, Chung HK, Yu DY, Lee KK and
Kwon OY. Methimazole as an antioxidant and
immunomodulator in thyroid cells: mechanisms
involving interferon-γ signaling and H2O2
scavenging. Mol. Pharmacol. (2001) 60: 972-80.
(23) Abalovich M, Llesuy S, Gutierrez S and Repetto
M. Peripheral parameters of oxidative stress in
Graves’ disease: the effects of methimazole and
131 iodine treatments. Clin. Endocrinol. (2003) 59:
321-7.
(24) Jansson R, Dahlberg PA, Johansson H and
Lindström B. Intrathyroidal concentrations of
methimazole in patients with Graves’ disease. J.
Clin. Endocrinol. Metab. (1983) 57: 129-32.
(25) Low L, McCruden D, Alexander W, Hilditch
T, Skellern G and Knight B. Intrathyroidal
iodide binding rates and plasma methimazole
concentrations in hyperthyroid patients on small
doses of carbimazole. Br. J. Clin. Pharmacol.
(1981) 12: 315-8.
(26) Taurog A and Dorris ML. A reexamination of the
proposed inactivation of thyroid peroxidase in the
rat thyroid by propylthiouracil. Endocrinology
(1989) 124: 3038-42.
(27) Benker G and Reinwein D. Pharmacokinetics of
antithyroid drugs. Klin. Wochenschr. (1982) 60:
531-9.
(28) Kampmann JP and Hansen JM. Clinical
pharmacokinetics of antithyroid drugs. Clin.
Pharmacokinet. (1981) 6: 401-28.
(29) Cooper DS, Saxe VC, Meskell M, Maloof F and
Ridgway EC. Acute effects of propylthiouracil
(PTU) on thyroidal iodide organification
and peripheral iodothyronine deiodination:
correlation with serum PTU levels measured by
radioimmunoassay. J. Clin. Endocrinol. Metab.
(1982) 54: 101-7.
(30) Kampmann J and Hansen JM. Serum protein
binding of propylthiouracil. Br. J. Clin. Pharmacol.
(1983) 16: 549-52.
(31) Cooper DS, Bode HH, Nath B, Saxe V, Maloof
F and Ridgway EC. Methimazole pharmacology
in man: studies using a newly developed
radioimmunoassay for methimazole. J. Clin.
Endocrinol. Metab. (1984) 58: 473-9.
(32) Jansson R, Lindström B and Dahlberg P.
Pharmacokinetic properties and bioavailability
of methimazole. Clin. Pharmacokinet. (1985) 10:
443-50.
(33) McCruden D, Hilditch T, Connell J, McLellan
A, Robertson J and Alexander W. Duration of
antithyroid action of methimazole estimated with 
10
Abdi H et al. / IJPR (2019), 18 (Special Issue): 1-12
an intravenous perchlorate discharge test. Clin.
Endocrinol. (1987) 26: 33-9.
(34) Cooper DS, Steigerwalt S and Migdal S.
Pharmacology of propylthiouracil in thyrotoxicosis
and chronic renal failure. Arch. Intern. Med. (1987)
147: 785-6.
(35) Azizi F, Takyar M, Madreseh E and Amouzegar
A. Treatment of toxic multinodular goiter:
Comparison of radioiodine and long-term
methimazole treatment. Thyroid (2019) 29: 625-
30.
(36) Cooper DS. Antithyroid drugs. N. Engl. J. Med.
(2005) 352: 905-17.
(37) Azizi F. The safety and efficacy of antithyroid
drugs. Expert Opin. Drug Saf. (2006) 5: 107-16.
(38) Andersen SL and Laurberg P. Managing
hyperthyroidism in pregnancy: current
perspectives. Int. J. Women’s Health (2016) 8:
497-504.
(39) Abraham P, Avenell A, Park CM, Watson WA and
Bevan JS. A systematic review of drug therapy
for Graves’ hyperthyroidism. Eur. J. Endocrinol.
(2005) 153: 489-98.
(40) Razvi S, Vaidya B, Perros P and Pearce SH. What
is the evidence behind the evidence-base? The
premature death of block-replace antithyroid drug
regimens for Graves’ disease. Eur. J. Endocrinol.
(2006) 154: 783-6.
(41) Weetman A, Ratanachaiyavong S, Middleton G,
Love W, John R, Owen G, Darke C, Lazarus J,
Hall R and McGregor A. Prediction of outcome in
Graves’ disease after carbimazole treatment. Q. J.
Med. (1986) 59: 409-19.
(42) Wiersinga WM. Graves’ disease: Can it be cured?
Endocrinol. Metab. (2019) 34: 29-38.
(43) Struja T, Fehlberg H, Kutz A, Guebelin L, Degen C,
Mueller B and Schuetz P. Can we predict relapse in
Graves’ disease? Results from a systematic review
and meta-analysis. Eur. J. Endocrinol. (2017) 176:
87-97.
(44) Vos XG, Endert E, Zwinderman A, Tijssen JG and
Wiersinga WM. Predicting the risk of recurrence
before the start of antithyroid drug therapy in
patients with Graves’ hyperthyroidism. J. Clin.
Endocrinol. Metab. (2016) 101: 1381-9.
(45) Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L,
Poppe K and Pearce SH. 2018 European Thyroid
Association guideline for the management of
Graves’ hyperthyroidism. Eur. Thyroid J. (2018) 7:
167-86.
(46) Tamai H, Nakagawa T, Fukino O, Ohsako N,
Shinzato R, Suematsu H, Kuma K, Matsuzuka F
and Nagataki S. Thionamide therapy in Graves’
disease: relation of relapse rate to duration of
therapy. Ann. Intern. Med. (1980) 92: 488-90.
(47) Reinwein D, Benker G, Lazarus J and Alexander
W. A prospective randomized trial of antithyroid
drug dose in Graves’ disease therapy. European
Multicenter Study Group on Antithyroid Drug
Treatment. J. Clin. Endocrinol. Metab. (1993) 76:
1516-21.
(48) Vitti P, Rago T, Chiovato L, Pallini S, Santini F,
Fiore E, Rocchi R, Martino E and Pinchera A.
Clinical features of patients with Graves’ disease
undergoing remission after antithyroid drug
treatment. Thyroid (1997) 7: 369-75.
(49) Sundaresh V, Brito JP, Wang Z, Prokop LJ, Stan
MN, Murad MH and Bahn RS. Comparative
effectiveness of therapies for Graves’
hyperthyroidism: a systematic review and network
meta-analysis. J. Clin. Endocrinol. Metab. (2013)
98: 3671-7.
(50) Allannic H, Fauchet R, Orgiazzi J, Orgiazzi A,
Genetet B, Lorcy Y, Guerrier AL, Delambre C and
Derennes V. Antithyroid drugs and Graves’ disease:
a prospective randomized evaluation of the efficacy
of treatment duration. J. Clin. Endocrinol. Metab.
(1990) 70: 675-9.
(51) García-Mayor RV, Paramo C, Cano RL, Mendez
LP, Galofre J and Andrade A. Antithyroid drug and
Graves’ hyperthyroidism. Significance of treatment
duration and TRAb determination on lasting
remission. J. Endocrinol. Invest. (1992) 15: 815-20.
(52) Maugendre D, Gatel A, Campion L, Massart
C, Guilhem I, Lorcy Y, Lescouarch J, Herry J
and Allannic H. Antithyroid drugs and Graves’
disease—prospective randomized assessment of
long-term treatment. Clin. Endocrinol. (1999) 50:
127-32.
(53) Weetman A, Pickerill A, Watson P, Chatterjee V
and Edwards O. Treatment of Graves’ disease with
the block-replace regimen of antithyroid drugs: the
effect of treatment duration and immunogenetic
susceptibility on relapse. Q. J. Med. (1994) 87:
337-41.
(54) Lippe BM, Landaw EM and Kaplan SA.
Hyperthyroidism in children treated with long term
medical therapy: twenty-five percent remission
every two years. J. Clin. Endocrinol. Metab.
(1987) 64: 1241-5.
(55) Barrio R, López-Capapé M, Martinez-Badás I,
Carrillo A, Moreno JC and Alonso M. Graves’
disease in children and adolescents: Response to
long-term treatment. Acta Paediatr. (2005) 94:
1583-9.
(56) Sato H, Minagawa M, Sasaki N, Sugihara S,
Kazukawa I, Minamitani K, Wataki K, Konda
S, Inomata H and Sanayama K. Comparison 
11
Antithyroid drugs
of methimazole and propylthiouracil in the
management of children and adolescents with
Graves’ disease: efficacy and adverse reactions
during initial treatment and long-term outcome. J.
Pediatr. Endocrinol. Metab. (2011) 24: 257-63.
(57) Chen DY, Jing J, Schneider PF and Chen TH.
Comparison of the long-term efficacy of low dose
131I versus antithyroid drugs in the treatment of
hyperthyroidism. Nucl. Med. Commun. (2009) 30:
160-8.
(58) Elbers L, Mourits M and Wiersinga W. Outcome of
very long-term treatment with antithyroid drugs in
Graves’ hyperthyroidism associated with Graves’
orbitopathy. Thyroid (2011) 21: 279-83.
(59) Azizi F and Malboosbaf R. Long-term antithyroid
drug treatment: a systematic review and metaanalysis. Thyroid (2017) 27: 1223-31.
(60) Azizi F, Ataie L, Hedayati M, Mehrabi Y and
Sheikholeslami F. Effect of long-term continuous
methimazole treatment of hyperthyroidism:
comparison with radioiodine. Eur. J. Endocrinol.
(2005) 152: 695-701.
(61) Laurberg P, Berman DC, Andersen S and
Bülow Pedersen I. Sustained control of Graves’
hyperthyroidism during long-term low-dose
antithyroid drug therapy of patients with severe
Graves’ orbitopathy. Thyroid (2011) 21: 951-6.
(62) Azizi F, Amouzegar A, Tohidi M, Hedayati M,
Khalili D, Cheraghi L, Mehrabi Y and Takyar
M. Increased remission rates after long-term
methimazole therapy in patients with Graves’
disease: results of a randomized clinical trial.
Thyroid (2019) 29: 1192-200.
(63) Léger J, Gelwane G, Kaguelidou F, Benmerad
M, Alberti C and Group FCGDS. Positive impact
of long-term antithyroid drug treatment on the
outcome of children with Graves’ disease: national
long-term cohort study. J. Clin. Endocrinol. Metab.
(2012) 97: 110-9.
(64) Azizi F, Takyar M, Madreseh E and Amouzegar
A. Long-term Methimazole Therapy in juvenile
Graves’ disease: A randomized trial. Pediatrics
(2019) 143: e20183034.
(65) Bahn RS. Graves’ ophthalmopathy. N. Engl. J.
Med. (2010) 362: 726-38.
(66) Li H, Xiang N, Hu W and Jiao X. Relation between
therapy options for Graves’ disease and the course
of Graves’ ophthalmopathy: a systematic review
and meta-analysis. J. Endocrinol. Invest. (2016)
39: 1225-33.
(67) Ma C, Xie J, Wang H, Li J and Chen S. Radioiodine
therapy versus antithyroid medications for Graves’
disease. Cochrane Database Syst. Rev. (2016) 2:
CD010094.
(68) Glinoer D and Cooper DS. The propylthiouracil
dilemma. Curr. Opin. Endocrinol. Diabetes Obes.
(2012) 19: 402-7.
(69) Andrès E, Zimmer J, Mecili M, Weitten T, Alt
M and Maloisel F. Clinical presentation and
management of drug-induced agranulocytosis.
Expert Rev. Hematol. (2011) 4: 143-51.
(70) Wang MT, Lee WJ, Huang TY, Chu CL and Hsieh
CH. Antithyroid drug-related hepatotoxicity in
hyperthyroidism patients: a population-based
cohort study. Br. J. Clin. Pharmacol. (2014) 78:
619-29.
(71) Yang J, Li LF, Xu Q, Zhang J, Weng WW, Zhu YJ
and Dong MJ. Analysis of 90 cases of antithyroid
drug-induced severe hepatotoxicity over 13 years
in China. Thyroid (2015) 25: 278-83.
(72) Suzuki N, Noh JY, Hiruma M, Kawaguchi A,
Morisaki M, Ohye H, Suzuki M, Matsumoto M,
Kunii Y and Iwaku K. Analysis of antithyroid
drug-induced severe liver injury in 18,558 newly
diagnosed patients with Graves’ disease in Japan.
Thyroid (2019) 29: 1390-8.
(73) Huang MJ and Liaw YF. Clinical associations
between thyroid and liver diseases. J. Gastroenterol.
Hepatol. (1995) 10: 344-50.
(74) Gürlek A, Çobankara V and Bayraktar M. Liver tests
in hyperthyroidism: effect of antithyroid therapy.
J. Clin. Gastroenterol. (1997) 24: 180-3.
(75) Akmal A and Kung J. Propylthiouracil,
and methimazole, and carbimazole-related
hepatotoxicity. Expert Opin. Drug Saf. (2014) 13:
1397-406.
(76) Cooper DS, Kaplan MM, Ridgway EC, Maloof F
and Daniels GH. Alkaline phosphatase isoenzyme
patterns in hyperthyroidism. Ann. Intern. Med.
(1979) 90: 164-8.
(77) Azizi F and Malboosbaf R. Safety of long-term
antithyroid drug treatment? A systematic review. J.
Endocrinol. Invest. (2019) 42: 1273-83.
(78) Alexander EK, Pearce EN, Brent GA, Brown RS,
Chen H, Dosiou C, Grobman WA, Laurberg P,
Lazarus JH and Mandel SJ. 2017 Guidelines of the
American Thyroid Association for the diagnosis
and management of thyroid disease during
pregnancy and the postpartum. Thyroid (2017) 27:
315-89.
(79) Gardner DF, Cruikshank DP, HAYS PM and Cooper
DS. Pharmacology of propylthiouracil (PTU)
in pregnant hyperthyroid women: correlation of
maternal PTU concentrations with cord serum
thyroid function tests. J. Clin. Endocrinol. Metab.
(1986) 62: 217-20.
(80) Momotani N, Yoshimura Noh J, Ishikawa N and
Ito K. Effects of propylthiouracil and methimazole 
12
Abdi H et al. / IJPR (2019), 18 (Special Issue): 1-12
on fetal thyroid status in mothers with Graves’
hyperthyroidism. J. Clin. Endocrinol. Metab.
(1997) 82: 3633-6.
(81) Wing DA, Millar LK, Koonings PP, Montoro MN
and Mestman JH. A comparison of propylthiouracil
versus methimazole in the treatment of
hyperthyroidism in pregnancy. Am. J. Obstet.
Gynecol. (1994) 170: 90-5.
(82) Yoshihara A, Noh J, Yamaguchi T, Ohye H, Sato
S, Sekiya K, Kosuga Y, Suzuki M, Matsumoto M
and Kunii Y. Treatment of graves’ disease with
antithyroid drugs in the first trimester of pregnancy
and the prevalence of congenital malformation. J.
Clin. Endocrinol. Metab. (2012) 97: 2396-403.
(83) Korelitz JJ, McNally DL, Masters MN, Li SX, Xu
Y and Rivkees SA. Prevalence of thyrotoxicosis,
antithyroid medication use, and complications
among pregnant women in the United States.
Thyroid (2013) 23: 758-65.
(84) Song R, Lin H, Chen Y, Zhang X and Feng W.
Effects of methimazole and propylthiouracil
exposure during pregnancy on the risk of neonatal
congenital malformations: A meta-analysis. PLoS
One (2017) 12: e0180108.
(85) Andersen SL, Olsen J, Wu CS and Laurberg
P. Birth defects after early pregnancy use of
antithyroid drugs: a Danish nationwide study. J.
Clin. Endocrinol. Metab. (2013) 98: 4373-81.
(86) Seo GH, Kim TH and Chung JH. Antithyroid
drugs and congenital malformations: a nationwide
Korean cohort study. Ann. Intern. Med. (2018)
168: 405-13.
(87) Korevaar TI and Peeters RP. Antithyroid drugs and
congenital malformations. Nat. Rev. Endocrinol.
(2018) 14: 328.
(88) Kampmann JP, Hansen JM, Johansen K and
Helweg J. Propylthiouracil in human milk: revision
of a Dogma. Obstet. Gynecol. Surv. (1981) 36: 15.
(89) Azizi F, Khoshniat M, Bahrainian M and Hedayati
M. Thyroid function and intellectual development
of infants nursed by mothers taking methimazole.
J. Clin. Endocrinol. Metab. (2000) 85: 3233-8.
(90) Azizi F, Khamseh M, Bahreynian M and Hedayati
M. Thyroid function and intellectual development
of children of mothers taking methimazole during
pregnancy. J. Endocrinol. Invest. (2002) 25: 586-9.
(91) Azizi F, Bahrainian M, Khamseh ME and
Khoshniat M. Intellectual development and thyroid
function in children who were breast-fed by
thyrotoxic mothers taking methimazole. J. Pediatr.
Endocrinol. Metab. (2003) 16: 1239-44.
(92) Momotani N, Yamashita R, Makino F, Noh JY,
Ishikawa N, Ito K and Ito K. Thyroid function in
wholly breast-feeding infants whose mothers take
high doses of propylthiouracil. Clin. Endocrinol.
(2000) 53: 177-81.
(93) American Academy of Pediatrics Committee on
Drugs. The transfer of drugs and other chemicals
into human milk.. Pediatrics (2001) 108: 776-89.